European Archives - Page 164 of 1113 - European Medical Journal

New Data Challenge Traditional Gastroparesis Diagnostics

Gastroparesis diagnoses based solely on gastric emptying studies may overlook broader gastrointestinal dysmotility, necessitating a shift in diagnostic approaches.

Increased Cardiovascular Risks for Patients with Vitiligo

Conditions such as cerebral infarction, acute myocardial infarction, pulmonary embolism, and venous thrombosis were more prevalent among those with vitiligo.

How Menopausal Hormone Therapy Affects the Brain

Discover how menopausal hormone therapy impacts brain health based on age, duration, and surgical history. Personalised approaches to MHT could improve women’s neurological outcomes.

Recaticimab Achieves LDL-C Reductions in Hypercholesterolemia with Extended Dosing Intervals

Recaticimab cuts LDL-C by over 60% with 12-week dosing, offering a promising lipid-lowering option for nonfamilial hypercholesterolemia patients on stable statin therapy.

Machine Learning Predicts Sepsis-Associated ARDS and Mortality Risks

Machine learning predicts occurrence and mortality of sepsis-associated ARDS with high accuracy, study reveals.

Improved Diagnostic Tool for Clear Cell Renal Cell Carcinoma

Diagnostic superiority of [68Ga]Ga-NYM046 PET/CT over the conventional [18F]FDG PET/CT in detecting clear cell renal cell carcinoma

Scoring System Predicts Disease Risk After Stem Cell Transplant in Leukaemia

A study has developed a scoring system to predict the risk of disease recurrence after stem cell transplantation in leukaemia patients

Semaglutide Tops USA Drug Sales Amidst Rising Eligibility and Cost Concerns

In 2023, semaglutide emerged as the top-selling drug in the USA, generating $13.8 billion in sales.

Rare Gene Variant Protects against Type 2 Asthma

This variant results in reduced STAT6 protein levels, dampened IL-4 responses, and lower IgE and eosinophil counts in the blood.

First anti-TFPI for haemophilia approved in EU

Pfizer’s anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.